Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML)

Trial Profile

Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cytarabine (Primary) ; Mitoxantrone (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 24 Oct 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
    • 06 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017 as per ClinicalTrials.gov record.
    • 06 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jul 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top